Biotech’s key upcoming clinical results

After delving into the key upcoming catalysts for big pharma, Evaluate Vantage has found the big data reveals expected for biotech companies with a market cap of at least $1bn.

Moderna will report vaccine data in cytomegalovirus (CMV) and respiratory syncytial virus (RSV); although the group lags competitors in the latter, it looks to have the lead in the former. Elsewhere, Biomarin will report three-year data with its haemophilia A gene therapy Roctavian, a key metric for the FDA, and Daiichi is taking a solo approach with its latest antibody-drug conjugate patritumab deruxtecan, with data in lung cancer.